Stem cell therapy for Parkinson's disease: where do we stand?
A major neuropathological feature of Parkinson's disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.
Roybon
Laurent
L
Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund University, BMC A10, 22184 Lund, Sweden. laurent.roybon@mphy.lu.se
Christophersen
Nicolaj S
NS
Brundin
Patrik
P
Li
Jia-Yi
JY
D000818:Animals; D006801:Humans; D010300:Parkinson Disease / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000639:trends*